Merck KGaA isn't interested in a big deal; India caps more drug prices; Rottapharm IPO scrapped;

@FiercePharma: Top-read on FP this weekend: Sun issues third recall since announcing deal to buy Ranbaxy. Article | Follow @FiercePharma

@TracyStaton: ICYMI: MannKind says it won't launch Afrezza without a partner. We updated our story. | Follow @TracyStaton

@EricPFierce: ICYMI last week: Weak link in the supply chain. Pharmacist walks out of NY hospital with 1,500 oxycodone tabs. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI: Solid PhIII brings Sanofi closer to blockbuster dengue sales. FierceVaccines story | Follow @CarlyHFierce

> Merck KGaA's pharma chief, Stefan Oschmann, says he's not looking for a merger of equals, but is shopping for mid-sized acquisitions. Report

> India has capped prices on more than 100 drugs in a move likely to slash profit margins at local units of multinational drugmakers, including Sanofi ($SNY) and Abbott Laboratories ($ABT). Report

> Nestlé's new dermatology unit Galderma amped up its partnership with the French drugmaker Ipsen, with plans to boost sales of a Botox competitior. Report

> Italy's Rovati family can't catch a break: After failing to sell Rottapharm, the family proposed an IPO, but investors wouldn't bite. Report

Medical Device News

@FierceMedDev: Massachusetts med tech outfit wins $1M from NIH to develop pediatric stent system. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI last week: FDA clears oral sleep apnea device, as search for CPAP alternatives continues. Story | Follow @StacyALawrence

@VarunSaxena2: FDA panel recommends stronger labeling, limiting use of power morcellation--agency may go farther. Article | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. More | Follow @MichaelGFierce

@EmilyWFierce: Global infectious diseases are infiltrating the Times' crossword puzzles. Here's a roundup of clues: More | Follow @EmilyWFierce

> Virtual Finger provides faster, better way to study 3D images. Item

> Virtual reality headset and Google Glass team up in Spanish surgery. Report

Biotech News

@FierceBiotech: Fresh off Phase III success, Otonomy shoots for an $86M IPO. Story | Follow @FierceBiotech

@JohnCFierce: I'm soon going offline for a week. will be holding down the fort. Please postpone all big news until I get back. :) | Follow @JohnCFierce

@DamianFierce: Via @WSJ, $ABBV + $SHPG would leapfrog $LLY. More | Follow @DamianFierce

@EmilyMFierce: Like in Humans, Genes Drive Half of Chimp Intelligence, Study Finds via . Article | Follow @EmilyMFierce

> Does crowdfunding work in biotech? Item

> President's advisory group calls for clinical trial changes, incentives for antibiotics R&D. More

> Roche and Exelixis herald a Phase III victory for their melanoma combo. News

CRO News

> China's HD Bio teams with Marshall U. for cancer R&D. Article

> CMOs eye Russia for growth. Item

> InVentiv joins a nonprofit effort to make trials more efficient. News

> Risk-sharing CRO Ergomed banks $18.9M and awaits a U.K. IPO. Story

> U.K. CRO emerges from $100M in deals with plans for more M&A. Article

Biotech IT News

> Google creates new cash source for European biotech IT startups with $100M VC fund. News

> Row over IT focus of Europe's brain project prompts 280 scientists to threaten a boycott. Story

> PHT prioritizes Android over Apple in preparation for 'bring your own device' trials. Article

> FDA warns Gilead over 'misleading' paid search link. Item

> After working to mimic the brain for 9 years, Numenta reflects on limitations of today's hardware. Story

Animal Health News

> PEDv diagnostic hits market as vets predict 2.5 million more deaths. Story

> U.K. animal care company profits from generic pet meds. Article

> Industry Voices: How to win at animal health. Report

> Vets may soon be able to carry scheduled drugs. News

> Report: China animal vaccine market up by 26%. Story

And Finally... New York Gov. Andrew Cuomo is catching flak for his plans to use Gilead Sciences' ($GILD) Truvada to prevent the spread of HIV. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.